IN2013DE02954A - - Google Patents
Info
- Publication number
- IN2013DE02954A IN2013DE02954A IN2954DE2013A IN2013DE02954A IN 2013DE02954 A IN2013DE02954 A IN 2013DE02954A IN 2954DE2013 A IN2954DE2013 A IN 2954DE2013A IN 2013DE02954 A IN2013DE02954 A IN 2013DE02954A
- Authority
- IN
- India
- Prior art keywords
- generaration
- nitro
- drugs
- agents
- tubercular
- Prior art date
Links
- 239000000814 tuberculostatic agent Substances 0.000 abstract 2
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 abstract 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 abstract 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 1
- FSIULLLXSORYSP-UHFFFAOYSA-N [N+](=O)([O-])N1C=NC=2NC(OC=21)[N+](=O)[O-] Chemical class [N+](=O)([O-])N1C=NC=2NC(OC=21)[N+](=O)[O-] FSIULLLXSORYSP-UHFFFAOYSA-N 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 229940124976 antitubercular drug Drugs 0.000 abstract 1
- 239000004202 carbamide Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 208000036984 extensively drug-resistant tuberculosis Diseases 0.000 abstract 1
- 150000002545 isoxazoles Chemical class 0.000 abstract 1
- 201000009671 multidrug-resistant tuberculosis Diseases 0.000 abstract 1
- 125000000565 sulfonamide group Chemical group 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 150000003536 tetrazoles Chemical class 0.000 abstract 1
- 150000003852 triazoles Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14725544.2A EP3052503B1 (en) | 2013-10-04 | 2014-03-31 | 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles and a process for the preparation thereof |
| IN2954DE2013 IN2013DE02954A (el) | 2013-10-04 | 2014-03-31 | |
| JP2016520053A JP6532457B2 (ja) | 2013-10-04 | 2014-03-31 | ６−ニトロ−２，３−ジヒドロイミダゾ［２，１−ｂ］オキサゾール及びこれらの調製方法 |
| ES14725544T ES2707362T3 (es) | 2013-10-04 | 2014-03-31 | 6-nitro-2,3-dihidroimidazo [2,1-b] oxazoles y un procedimiento de preparación de los mismos |
| PCT/IN2014/000202 WO2015049693A1 (en) | 2013-10-04 | 2014-03-31 | 6-NITRO-2,3-DIHYDROIMIDAZO[2,1-b]OXAZOLES AND A PROCESS FOR THE PREPARATION THEREOF |
| US15/027,137 US9845330B2 (en) | 2013-10-04 | 2014-03-31 | 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles and a process for the preparation thereof |
| TW103120596A TWI654192B (zh) | 2013-10-04 | 2014-06-13 | ６－硝基－２，３－二氫咪唑并［２，１－ｂ］噁唑及其製備方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2954DE2013 IN2013DE02954A (el) | 2013-10-04 | 2014-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2013DE02954A true IN2013DE02954A (el) | 2015-04-10 |
Family
ID=50771310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2954DE2013 IN2013DE02954A (el) | 2013-10-04 | 2014-03-31 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9845330B2 (el) |
| EP (1) | EP3052503B1 (el) |
| JP (1) | JP6532457B2 (el) |
| ES (1) | ES2707362T3 (el) |
| IN (1) | IN2013DE02954A (el) |
| TW (1) | TWI654192B (el) |
| WO (1) | WO2015049693A1 (el) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6467042B2 (ja) | 2014-10-21 | 2019-02-06 | カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ | 抗マイコバクテリア剤としての置換１，２，３−トリアゾール−１−イル−メチル−２，３−ジヒドロ−２−メチル−６−ニトロイミダゾ［２，１−ｂ］オキサゾールとその調製方法 |
| CN108059623B (zh) * | 2016-11-07 | 2021-07-13 | 浙江省化工研究院有限公司 | 一类含取代芳基联异噁唑芳基脒类化合物、其制备方法及应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI347946B (en) * | 2002-10-11 | 2011-09-01 | Otsuka Pharma Co Ltd | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound |
| ATE410430T1 (de) * | 2003-10-31 | 2008-10-15 | Otsuka Pharma Co Ltd | 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose |
| JP4761756B2 (ja) * | 2003-10-31 | 2011-08-31 | 大塚製薬株式会社 | ２，３−ジヒドロイミダゾ［２，１−ｂ］オキサゾ−ル化合物 |
| JP4787529B2 (ja) * | 2004-04-09 | 2011-10-05 | 大塚製薬株式会社 | 医薬組成物 |
| US7049876B2 (en) | 2004-10-25 | 2006-05-23 | Delphi Technologies, Inc. | Level shift circuits and related methods |
| MX2008001210A (es) | 2005-07-28 | 2008-03-24 | Otsuka Pharma Co Ltd | Composicion farmaceutica que comprende derivados de 2,3-dihidro-6-nitroimidazo{2,1-b]oxazol. |
| US7666864B2 (en) * | 2008-03-26 | 2010-02-23 | Global Alliance For Tb Drug Development | Bicyclic nitroimidazole-substituted phenyl oxazolidinones |
-
2014
- 2014-03-31 EP EP14725544.2A patent/EP3052503B1/en active Active
- 2014-03-31 IN IN2954DE2013 patent/IN2013DE02954A/en unknown
- 2014-03-31 ES ES14725544T patent/ES2707362T3/es active Active
- 2014-03-31 WO PCT/IN2014/000202 patent/WO2015049693A1/en active Application Filing
- 2014-03-31 JP JP2016520053A patent/JP6532457B2/ja active Active
- 2014-03-31 US US15/027,137 patent/US9845330B2/en active Active
- 2014-06-13 TW TW103120596A patent/TWI654192B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2707362T3 (es) | 2019-04-03 |
| TWI654192B (zh) | 2019-03-21 |
| US20160244462A1 (en) | 2016-08-25 |
| EP3052503A1 (en) | 2016-08-10 |
| US9845330B2 (en) | 2017-12-19 |
| EP3052503B1 (en) | 2018-10-24 |
| JP6532457B2 (ja) | 2019-06-19 |
| WO2015049693A1 (en) | 2015-04-09 |
| JP2016531898A (ja) | 2016-10-13 |
| TW201514184A (zh) | 2015-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017502298A1 (en) | Antibacterial compounds | |
| MX2018015656A (es) | Compuestos heterociclicos como antibacterianos. | |
| PH12020550622A1 (en) | Kras g12c inhibitors | |
| MX2018015657A (es) | Compuestos heterociclico como antibacterianos. | |
| MX2018013983A (es) | Inhibidores g12c de kras. | |
| PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| PH12016501099A1 (en) | Materials and methods for controlling infections | |
| IL259836B (en) | Dimeric macrocyclic cations, complexes containing them and their uses as contrast agents | |
| PH12016500511A1 (en) | Selective grp94 inhibitors and uses thereof | |
| PH12020500255A1 (en) | Use of nk-1 receptor antagonist serlopitant in pruritus | |
| MX2015008697A (es) | Tratamiento contra la degeneración macular relacionada con la edad. | |
| EP3054953A4 (en) | Hdac inhibitors, alone or in combination with pi3k inhibitors, for treating non-hodgkin's lymphoma | |
| EP2958913A4 (en) | SPHINGOSINE 1 PHOSPHATE RECEPTOR AGONISTS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREFOR AS ACTIVE AGENT | |
| MX2016013280A (es) | Composiciones topicas para el alivio del dolor, manufactura y uso. | |
| TN2016000084A1 (en) | Nsaid and sigma receptor ligand combinations | |
| MX2021005172A (es) | Compuestos de union a nhe3 (intercambiador de sodio-hidrogeno 3) y metodos para inhibir el transporte de fosfato. | |
| PH12016501095A1 (en) | Gabapentinoids and sigma receptor ligands combinations | |
| NZ702415A (en) | Methods for treating neutropenia using retinoid agonists | |
| MY186475A (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
| WO2015009591A3 (en) | Treatment for melanoma | |
| AU2013208104A8 (en) | Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof | |
| WO2015066302A3 (en) | Compositions, methods of use, and methods of treatment | |
| IN2013DE02954A (el) | ||
| MX2018004881A (es) | Aditivo para tratamiento posterior interno de composiciones aglutinantes minerales. | |
| MX2015012344A (es) | 4-ciano-n-(2-(4,4-dimetilciclohex-1-en-1-il)-6-(2,2,6,6-tetrameti ltetrahidro-2h-piran-4-il)piridin-3-il)-1h-imidazol-2-carboxamida para el tratamiento de linfona de hodgkin. |